131 related articles for article (PubMed ID: 38880112)
1. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Korotych O; Achar J; Gurbanova E; Hovhannesyan A; Lomtadze N; Ciobanu A; Skrahina A; Dravniece G; Kuksa L; Rich M; Khachatryan N; Germanovych M; Kadyrov A; Terleieva I; Akhundova I; Adenov M; Durdyeva M; Kiria N; Parpieva N; Yatskevich N; Jumayev R; Nurov R; Diktanas S; Vilc V; Migliori GB; Yedilbayev A
Lancet Infect Dis; 2024 Jun; ():. PubMed ID: 38880112
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
[TBL] [Abstract][Full Text] [Related]
5. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J; Lee M; Kim DK; Kim JS; Jhun BW; Jo KW; Jeon D; Lee T; Lee JY; Park JS; Lee SH; Kang YA; Lee JK; Kwak N; Ahn JH; Shim TS; Kim SY; Kim S; Kim K; Seok KH; Yoon S; Kim YR; Kim J; Yim D; Hahn S; Cho SN; Yim JJ;
Lancet; 2022 Oct; 400(10362):1522-1530. PubMed ID: 36522208
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
7. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020.
Avaliani T; Sereda Y; Davtyan H; Tukvadze N; Togonidze T; Kiria N; Denisiuk O; Gozalov O; Ahmedov S; Hovhannesyan A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470088
[TBL] [Abstract][Full Text] [Related]
9. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
[TBL] [Abstract][Full Text] [Related]
10. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
11. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
[TBL] [Abstract][Full Text] [Related]
12. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
13. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
Lancet Infect Dis; 2024 May; ():. PubMed ID: 38768617
[TBL] [Abstract][Full Text] [Related]
14. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
Chiang CY; Lin CJ
Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
[TBL] [Abstract][Full Text] [Related]
15. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
Fregonese F; Ahuja SD; Akkerman OW; Arakaki-Sanchez D; Ayakaka I; Baghaei P; Bang D; Bastos M; Benedetti A; Bonnet M; Cattamanchi A; Cegielski P; Chien JY; Cox H; Dedicoat M; Erkens C; Escalante P; Falzon D; Garcia-Prats AJ; Gegia M; Gillespie SH; Glynn JR; Goldberg S; Griffith D; Jacobson KR; Johnston JC; Jones-López EC; Khan A; Koh WJ; Kritski A; Lan ZY; Lee JH; Li PZ; Maciel EL; Galliez RM; Merle CSC; Munang M; Narendran G; Nguyen VN; Nunn A; Ohkado A; Park JS; Phillips PPJ; Ponnuraja C; Reves R; Romanowski K; Seung K; Schaaf HS; Skrahina A; Soolingen DV; Tabarsi P; Trajman A; Trieu L; Banurekha VV; Viiklepp P; Wang JY; Yoshiyama T; Menzies D
Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509
[TBL] [Abstract][Full Text] [Related]
17. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan.
Rashitov M; Franke M; Trevisi L; Bekbolatova G; Shalimova J; Eshmetov G; Bektasov S; LaHood A; Arlyapova N; Osso E; Yedilbayev A; Korotych O; Ciobanu A; Skrahina A; Mitnick CD; Seung K; Algozhin Y; Rich ML
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38833593
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
20. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
Esmail A; Oelofse S; Lombard C; Perumal R; Mbuthini L; Goolam Mahomed A; Variava E; Black J; Oluboyo P; Gwentshu N; Ngam E; Ackerman T; Marais L; Mottay L; Meier S; Pooran A; Tomasicchio M; Te Riele J; Derendinger B; Ndjeka N; Maartens G; Warren R; Martinson N; Dheda K
Am J Respir Crit Care Med; 2022 May; 205(10):1214-1227. PubMed ID: 35175905
[No Abstract] [Full Text] [Related]
[Next] [New Search]
